Spotlight On... GlaxoSmithKline expands its 'electroceuticals' program; Pulmatrix teams with Capsugel; and more...

GlaxoSmithKline ($GSK), targeting the intersection of medicine and technology, is working with Nuviant Medical, using the company's devices to fuel preclinical research. Nuviant is at work on a device designed to treat chronic disease through neurostimulation, and GSK is licensing the platform to do its own R&D. The move is part of GSK's commitment to what it calls "electroceuticals," a program unveiled in 2013 that includes a $50 million fund to back startups in the field. Release

@FierceBiotech: Seven Bridges raises $45M to fuel drive to be the backbone of large-scale genome projects. More from FierceBiotechIT | Follow @FierceBiotech

@JohnCFierce: Got plenty of cash? Market carnage sets up a Darwinian showdown in biotech. Story | Follow @JohnCFierce

@DamianFierce: there must be at least one person at who also had NBA All-Star tickets and is just FURIOUS. | Follow @DamianFierce

> Capsugel and Pulmatrix ($PULM) have teamed up to develop new inhaled therapies, partnering to develop and manufacture treatments for COPD, cystic fibrosis and idiopathic pulmonary fibrosis. News

> Synergy Pharmaceuticals ($SGYP) signed a deal to apply Bind Therapeutics' ($BIND) drug delivery technology to an early-stage cancer treatment. Item

> Cellceutix ($CTIX) wrapped up a Phase I study for Kevetrin, a treatment for solid tumors, and is now blueprinting a Phase II effort. Release

Medical Device News

@FierceMedDev: ICYMI from FierceDrugDelivery: FDA says drug delivery devices need human factors validation testing. Article | Follow @FierceMedDev

@EmilyWFierce: Pfizer takes a $784M hit with Medicaid pricing settlement. FiercePharma story | Follow @EmilyWFierce

> Theranos sends plan to CMS for solving problems at beleaguered California lab. Report

> Data analysis startup cashes in on precision medicine trend with $45M in tow. Story

> GSK partners with Belgian neurostim startup in bioelectronic medicine research. More

> Stryker bulks up in emergency medicine with $1.3B purchase of Physio-Control. Article

Pharma News

@FiercePharma: Zoetis beats estimates in Q4 but dampens 2016 sales forecast on currency woes. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Eisai bulks up on bulk drugs for Japan's growing generics market. Doubling capacity in India. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI last week: Novartis takes aim at Remicade market with EU biosim rights from Pfizer. More | Follow @CarlyHFierce

> Merck's cholesterol meds Zetia, Vytorin lose final appeal for bigger CV market. Report

> Express Scripts steps up its Valeant feud with microscopic look at every claim. Story

> Pfizer takes a $784M hit with Medicaid pricing settlement. Article

Animal Health News

> VCA beats on earnings in Q4 with growth in animal hospital and lab businesses. Story

> Startup aims to match ailing pets with clinical trials that could help people, too. More

> Trupanion beats Q4 estimates as vet clinics snap up Express insurance product. Report

> Zoetis beats estimates in Q4 but dampens 2016 sales forecast on currency woes. Article

> Investors applaud Schein's record sales and earnings. Item

Biotech IT News

> Biogen allies with GSK in precompetitive computational biology collaboration. Report

> 10x Genomics strikes deals with Illumina, Agilent and Qiagen. News

> Illumina shares details of semiconductor-based sequencing device. Item

> Seven Bridges raises $45M to fuel drive to be the backbone of large-scale genome projects. Story

> Illumina, Icon land data deals with U.K. mass genome sequencing program. Article

Drug Delivery News

> Early-stage drug delivery implant targeting pancreatic cancer tumors showing promise. Report

> Shape, flexibility of nanoparticles give them an edge against cancer. More

> Amgen deploys West Pharma vials to store its injectable cancer med Imlygic. Item

> Gold nanoparticle clusters and bursts of infrared light eliminate post-surgery tumor cells. Story

> BioCryst stock in dumps after it terminates soft gel arm of its rare disease candidate. Article

Pharma Manufacturing News

> Pfizer recalls children's Advil in Canada; 'clumps' could cause dosing mistakes. More

> Vet drugmaker Chanelle Group putting €70M into Ireland plant. Item

> Perrigo recalling 200M units of antifungus drug over labeling mishap. Report

> Sun to ask for FDA reinspection of troubled Halol plant. Story

> Buffalo, NY-based drug developer says it will build biologics plant, hire 900. Article

Pharma Asia News

> Indonesia clears decks for foreign API manufacturers. Article

> China push to bring biotech talent home is paying off. More

> China healthcare exports need marketing, quality push after acquisitions: L.E.K. Story

> China renews consolidation drive for drug manufacture, wants TCM push. Article

> India's MedGenome pledges $10M for South Asia sequencing effort. Report

Suggested Articles

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.

The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.

Last year, Eli Lilly spent $1.6 billion to get its hands on Armo Biosciences and its lead asset, pegilodecakin. Today, that drug flopped.